Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Lipid Absorption01:24

Lipid Absorption

Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Lipid Digestion01:06

Lipid Digestion

Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role.

Journal of lipid research·2026
Same author

Response to PCSK9 Inhibition Based on LDL Receptor Function in Familial Hypercholesterolemia: A Nonrandomized Clinical Trial.

JAMA cardiology·2026
Same author

Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial.

The lancet. Diabetes & endocrinology·2025
Same author

Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial.

JAMA cardiology·2024
Same author

Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials.

Journal of clinical lipidology·2022
Same author

Targeting PCSK9 inhibitors to those who will benefit most.

The lancet. Diabetes & endocrinology·2022
Same journal

Managing patients with cardiovascular-kidney-metabolic syndrome: a guideline-driven practical guide for primary care physicians.

Postgraduate medicine·2026
Same journal

CV risk: if you aren't testing ACR, you aren't seeing the full picture.

Postgraduate medicine·2026
Same journal

Anti-TNF-induced vasculitis: analysis of data from the French national pharmacovigilance database.

Postgraduate medicine·2026
Same journal

Relationship of serum nesfatin-1 levels with body mass index and c-reactive protein in patients presenting to the emergency department with epileptic seizures.

Postgraduate medicine·2026
Same journal

Clinical pharmacokinetics of colistimethate sodium and formed colistin in patients with renal impairment or on dialysis modalities: a systematic review and implications for precision dosing.

Postgraduate medicine·2026
Same journal

The role of type D personality in pregnancy symptom severity, functional limitations, and maternal ambivalence.

Postgraduate medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 21, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

New evidence supporting aggressive lipid lowering.

Evan A Stein1

  • 1Metabolic and Atherosclerosis Research Center, University of Cincinnati Medical Center, Cincinnati, OH 45219, USA.

Postgraduate Medicine
|August 12, 2009
PubMed
Summary
This summary is machine-generated.

Aggressively lowering low-density lipoprotein cholesterol (LDL-C) may reduce coronary heart disease (CHD) events. Statins, like atorvastatin and rosuvastatin, are effective in achieving LDL-C targets for patients with hypercholesterolemia.

Related Experiment Videos

Last Updated: Jun 21, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Established link between low-density lipoprotein cholesterol (LDL-C) and coronary heart disease (CHD).
  • National Cholesterol Education Program (NCEP) guidelines recommend LDL-C < 100 mg/dL for high-risk patients.

Purpose of the Study:

  • To evaluate the benefits of aggressive LDL-C reduction beyond current NCEP targets.
  • To assess the efficacy of statins in achieving LDL-C goals.

Main Methods:

  • Review of recent studies on LDL-C reduction strategies.
  • Comparison of aggressive vs. moderate LDL-C reduction and conventional treatment.
  • Evaluation of statin efficacy, including atorvastatin and rosuvastatin.

Main Results:

  • Aggressive LDL-C reduction associated with reduced atherosclerosis progression.
  • Lower rates of revascularization and ischemic events observed with aggressive LDL-C lowering.
  • Statins, particularly rosuvastatin, demonstrate high efficacy in achieving LDL-C targets.

Conclusions:

  • Aggressive LDL-C reduction may offer additional cardiovascular benefits.
  • Statins are the primary pharmacologic agents for LDL-C management.
  • Current NCEP guidelines can be met for most patients using statin therapy.